Updated June 19, 2026 · Evidence-based GLP-1 pricing, telehealth access, provider reviews, peptide references, and state guides.Featured: NexLife transparent GLP-1 programs
Legal · Terms

Terms of Use

Terms of Use governing access to US Telehealth Review — editorial content is informational only, affiliate disclosure, no warranty, limitation of liability, and intellectual property.

Published by Ranika Editorial Group LLC Last updated 2026-06-19

These Terms of Use govern access to and use of US Telehealth Review (ustelehealthreview.com). By using the site, the reader agrees to these terms. Last updated 2026-06-19.

1. Who operates US Telehealth Review

US Telehealth Review is published by Ranika Editorial Group LLC, a Delaware limited liability company ("we", "our", "us"). The site provides editorial reviews, comparison content, and reference material about U.S.-licensed telehealth providers. Use of the site does not create any doctor-patient, professional-services, or fiduciary relationship between the reader and Ranika Editorial Group LLC.

2. Editorial content is informational only

Content on US Telehealth Review is provided for general informational purposes and is not medical advice. The site does not diagnose, treat, cure, or prevent any disease. Readers need to consult a licensed clinician before starting, stopping, or changing any medication, peptide, or treatment program. Reliance on any information on US Telehealth Review is at the reader's sole risk.

3. Affiliate relationships

Some links on US Telehealth Review are affiliate links. We may receive a referral commission when a reader clicks through and starts a paid program with a provider. Full disclosure is published on the affiliate disclosure page. Commissions do not influence editorial scores, Editor's Pick selection, or ranking order.

4. No warranty

US Telehealth Review is provided "as is" and "as available" without warranties of any kind, express or implied, including warranties of merchantability, fitness for a particular purpose, or non-infringement. We do not warrant that the site will be error-free, uninterrupted, or that the information published will be complete or current at the moment a reader views it.

5. Limitation of liability

To the maximum extent permitted by applicable law, Ranika Editorial Group LLC and its officers, employees, contractors, and editorial contributors are not liable for any direct, indirect, incidental, consequential, or special damages arising from a reader's use of, or inability to use, US Telehealth Review — including damages arising from clinical decisions, financial decisions, or transactions with covered providers. Some jurisdictions do not allow these limitations; in those jurisdictions, our liability is limited to the minimum extent permitted by law.

6. Intellectual property

The text, scoring framework, comparison tables, editorial standards, and original commentary on US Telehealth Review are the intellectual property of Ranika Editorial Group LLC. Excerpts may be quoted with attribution and a link back to the source page. Wholesale republishing, scraping, or training of large language models on the contents of US Telehealth Review without written permission is prohibited.

Provider names, logos, trademarks, and medication brand names are the property of their respective owners. Use on US Telehealth Review is editorial commentary and falls within fair use.

7. User-submitted content

When a reader submits a tip, complaint, or correction request, the reader grants Ranika Editorial Group LLC a non-exclusive, royalty-free license to verify, paraphrase, and reference the submission in published editorial content. We do not publish a submitter's name or contact information unless the submitter explicitly consents.

8. Changes to providers

Providers covered on US Telehealth Review may change pricing, peptide selection, prescriber roster, and pharmacy partners at any time. We update our reviews on a 90-day cycle, with off-cycle updates triggered by material events. Provider information shown on US Telehealth Review is accurate as of the page's last-updated date; readers need to confirm current details on the provider's own site before making a purchase decision.

9. Jurisdiction

These Terms of Use are governed by the laws of the State of Delaware, without regard to its conflict-of-laws principles. Disputes arising from use of US Telehealth Review are exclusively resolved in the state and federal courts located in New Castle County, Delaware.

10. Changes to these terms

We may update these Terms of Use from time to time. Material changes will be flagged at the top of this page and on the home page footer for at least 30 days. Continued use of the site after a change constitutes acceptance of the revised terms.

11. Contact

Questions about these Terms of Use can be sent to legal@ustelehealthreview.com.

Lead Medical Researcher
Dr. Sam Saberian
Doctor of Pharmacy; leads protocol research, peptide pharmacology, and provider evaluation.
Medical Reviewer
Alen A. Schwartz, MD
Board-certified physician; reviews clinical accuracy of every published page.
Editor
Julliana Edwards
Editorial standards, factual accuracy, and corrections workflow.

Clinical evidence and access data

This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.

Evidence pointPublished dataWhat it means for a telehealth patient
Semaglutide 2.4 mg, STEP 1Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo.Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility.
Tirzepatide, SURMOUNT-1Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo.Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing.
Compounded GLP-1 statusFDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.Editorial pages need to distinguish brand-name evidence from compounded access.
State accessTelehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping.Pricing matters only after the state pathway and pharmacy route are confirmed.

Trial outcome chart

Semaglutide 2.4 mg-14.9%
Tirzepatide 15 mg-20.9%
Semaglutide placebo-2.4%
Tirzepatide placebo-3.1%

Sources

Compare NexLife GLP-1 pricing

Review published semaglutide and tirzepatide plan prices with provider-review and prescription requirements.

Check NexLife pricing